Bar Harbor Wealth Management Reduces Holdings in Becton, Dickinson and Company (NYSE:BDX)

Bar Harbor Wealth Management trimmed its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 37.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,739 shares of the medical instruments supplier's stock after selling 2,193 shares during the quarter. Bar Harbor Wealth Management's holdings in Becton, Dickinson and Company were worth $901,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Jennison Associates LLC raised its stake in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier's stock valued at $99,562,000 after buying an additional 18,786 shares during the period. Norden Group LLC boosted its stake in Becton, Dickinson and Company by 2,086.7% in the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier's stock valued at $12,853,000 after purchasing an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC bought a new position in Becton, Dickinson and Company during the 1st quarter worth $11,998,000. Avity Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier's stock valued at $40,257,000 after acquiring an additional 5,527 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Becton, Dickinson and Company by 9.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier's stock worth $14,481,000 after acquiring an additional 5,006 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX opened at $243.75 on Friday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $262.23. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company has a market capitalization of $70.45 billion, a price-to-earnings ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42. The firm's fifty day moving average price is $237.01 and its two-hundred day moving average price is $235.28.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analysts' expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.96 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.56%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company's payout ratio is 83.70%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating on the stock in a research note on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Finally, Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.